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Abstract
The impact of viral co-infections and recently discovered viruses on the epidemiology of respiratory infections in children is still unclear.
To simultaneously detect viruses that are involved in the aetiology of respiratory infections, we used a DNA/RNA microarray assay that
identifies 17 different viruses or viral subtypes. Rhinopharyngeal washes were taken from 611 children (aged 1 month to 14 years) who
presented in the emergency department with respiratory infections from June 2010 to June 2011 and were treated as outpatients (299,
48.9%) or hospitalized (312, 51.1%). Lower respiratory tract infection was diagnosed more often in hospitalized children (68% versus
36%, p 0.001). Of 397 children in which microarrays detected viral infection (70.1%), a single virus was found in 228 (57.4%) and two
or more viruses in 169 (42.5%). The most prevalent viruses among children with positive samples were respiratory syncytial virus (RSV)
in 225 (56.6%), parainfluenza virus (PIV) in 118 (29.7%), rhinovirus (RV) in 73 (18.4%), followed by influenza in 56 (14.1%), adenoviruses
in 31 (7.8%), bocavirus in 25 (6.3%), human metapneumovirus in 15 (3.7%) and enteroviruses in 12 (3%). Most common viral co-infec-
tions were RSVA–RSVB in 46 children (27.2%), RSV–Influenza in 20 (11.8%), RSV–RV in 18 (10.6%) and PIV–RV in 13 (7.7%). Multiple
logistic regression analysis revealed that viral co-infections were associated with increased probability for hospitalization (OR 1.52, 95%
CI 1.01–2.29, p 0.04), and previous pneumococcal vaccination was associated with decreased probability for hospitalization (OR 0.52,
95% CI 0.33–0.81, p 0.004). We conclude that viral co-infections are involved in a significant proportion of children with an acute respi-
ratory infection and may increase the severity of clinical presentation and the risk for hospitalization.
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Introduction
Respiratory infections represent a major public health prob-
lem because of their high incidence and ease of spread in the
community [1]. Acute respiratory tract infections (ARTIs)
are associated with significant morbidity and are the com-
monest reason for outpatient visits and hospitalizations
among young children [2,3]. Viruses are a leading cause
of ARTIs with an epidemiological variability depending on
climate, season and regions [4].
Viral aetiology is still unclear in a significant proportion of
ARTIs and the role of viral co-infections is controversial
[5,6]. During the past decade, new respiratory viruses, such
as human metapneumovirus and human bocavirus, have been
discovered. The impact of these viruses on the global epide-
miology of ARTIs has not been fully elucidated [7,8]. More-
over, human rhinoviruses and enteroviruses, previously
identified in childhood upper respiratory tract infections,
have been suspected as major aetiological agents of lower
respiratory tract infections like bronchiolitis and pneumonia
in infants [9,10].
Viral respiratory diagnosis has traditionally relied on anti-
gen detection and virus isolation. The lack of sensitivity of
antigen detection, the delay in the results with virus isolation
and the limitations of detecting only cultivable viruses usually
made the diagnosis of respiratory viruses incomplete [11].
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Detection and identification of viral respiratory agents,
however, has improved in the last decade as the result of
new molecular techniques. Molecular technology has
increased sensitivity and accuracy, and the development of
multiplex amplifications makes it possible to detect a broad
panel of viruses simultaneously. Indeed, the use of a reverse
transcription (RT) -PCR DNA/RNA microarray system
allows the rapid and accurate detection of conventional and
newly discovered viral respiratory pathogens in paediatric
patients [12].
The purpose of this study was to investigate the role of
viral co-infections in ARTIs and to examine possible differ-
ences in the aetiology, clinical features and epidemiology of
such infections between non-hospitalized and hospitalized
children, using a DNA/RNA microarray assay.
Materials and Methods
Patients and samples
A prospective study of respiratory tract infections in children
was performed in the First Department of Paediatrics, Univer-
sity of Athens, ‘Aghia Sophia’ Children’s Hospital. The study
population included children aged from 1 month to 14 years
who presented in the emergency department with symptoms
of ARTIs and were treated as outpatients or hospitalized
between June 2010 and June 2011. Children were hospitalized
on the basis of the clinical severity, as determined by the
judgement of the attending physician. Demographic and clinical
data, and nasopharyngeal washes were taken from outpatient
children in the emergency department. For hospitalized chil-
dren, samples were taken at the time of admission to exclude
hospital-acquired infections and clinical data were taken during
their hospitalization and abstracted from medical records.
Children with chronic heart, liver, or kidney disease, cystic
fibrosis, or diabetes were reported as children with chronic
health problems. Children with at least one dose of conjugated
pneumococcal vaccine were regarded as vaccinated.
The ARTIs were classified into three categories: (i) upper
respiratory tract infections (URTIs) were diagnosed when
rhinitis, pharyngitis, laryngitis or otitis media were present in
the absence of lower respiratory tract infection (LRTI) signs;
(ii) LRTIs were diagnosed in the presence of signs of lower
airway involvement (tachypnoea, dyspnoea, wheezing, rales)
or a positive chest X-ray in the absence of URTIs; and (iii)
URTIs plus LRTIs were diagnosed with signs and symptoms
from both upper and lower respiratory tract such as laryn-
gotracheobronchitis, rhinitis and wheezing etc.
The study was approved by the hospital’s Ethics Commit-
tee and nasopharyngeal samples were collected after
informed consent was obtained from the children’s parents
and assent was given by the children. The samples were
tested using an RT-PCR DNA/RNA microarray system
(CLART Pneumovir DNA arrays assay; Genomica, Coslada,
Madrid, Spain) in the Department of Cytopathology, Univer-
sity Hospital Attikon.
Sample collection
A nasopharyngeal lavage sample was obtained from each
child using a standardized procedure. Each respiratory speci-
men was taken by introducing 5 mL of sterile saline solution
into the nasal fossa, maintaining the patient’s head leant back-
wards and then collect the solution in a sterile container
placed below nasal fossae, inclining the patient’s head. Sam-
ples were stored and processed according to the manufac-
turer’s instructions.
Nucleic acid extraction and DNA array assay
Total nucleic acid was extracted from 200 lL of each clinical
specimen. The CLART Pneumovir DNA arrays assay
detects and characterizes 17 common human viruses causing
respiratory infections in an 8-h procedure after nucleic acid
extraction. These viruses are: influenza virus (INFL) A, B and
C; parainfluenza virus (PIV) 1, 2, 3 and 4 (subtypes A and B);
respiratory syncytial virus type A (RSVA); respiratory syncy-
tial virus type B (RSVB); rhinovirus (RV); human metapneu-
movirus (HMPV) (subtypes A and B); enterovirus (EV)
(Echovirus); adenovirus (ADV); coronavirus (HCoV) (subtype
229E) and bocavirus (HBoV).
The detection is based on the amplification of specific
fragments of the viral genome using RT-PCR for amplification
of a specific 120–330-base-pair fragment of the viral genome.
During a 5-h RT-PCR/PCR amplification, the amplified prod-
ucts were labelled with biotin. Following amplification,
hybridization with specific probes immobilized sites of the
micro-array. After incubation with a streptavidin–peroxidase
conjugate, the addition of tetramethylbenzidine induced the
appearance of an insoluble product that precipitated at the
hybridization sites on the micro-array. The results were pro-
cessed by a microarray reader using specific software pro-
vided by the manufacturers, which allowed the automatic
detection and interpretation of the results, giving a full and
specific diagnosis of each analysis in a report.
Statistical analysis
Initially, descriptive statistics for the data were calculated
and the possible association of the hospitalization with the
examined variables was univariance tested using the Chi-
square or the Wilcoxon tests. In the next step multivariate
analysis was also performed through multiple logistic
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regression analysis where, the hospitalization status was con-
sidered as the dependent variable and the age (categorical,
three categories with baseline being 60+ months), sex (cate-
gorical with baseline: boys), a family member with respira-
tory viral infection (categorical with baseline: no), chronic
health problem (categorical with baseline: no), number of
wheezing episodes per year (ordered with an increment of
two episodes), fever on presentation (categorical with base-
line: no), bronchodilator use on presentation (categorical
with baseline: no), antibiotic use on presentation (categorical
with baseline: no), influenza vaccination (categorical with
baseline: no) and pneumococcal vaccination (at least one
dose) (categorical with baseline: no) as potential confound-
ers. Finally the viral co-infection was also introduced into
the above model as an additional variable (categorical with
baseline: no). Statistical analysis was performed with SAS,
(version 9.2).
Results
Demographic and clinical characteristics
Children’s demographic and clinical characteristics according
to their hospitalization status are presented in Table 1. A
total of 611 children (boys 56%) with ARTIs were included
in the study. In all, 312 (51.1%) were hospitalized and 299
(48.9%) were treated as outpatients. The median age was
28 months (IQR 10–59) but hospitalized children were youn-
ger (p 0.0001). An URTI was diagnosed in 235 children
(38%), LRTI in 320 (53%) and URTI plus LRTI in 54 (9%).
Hospitalized children were more often diagnosed with LRTI
(p 0.001), had a chronic health problem (p 0.002), had a
positive history for previous wheezing episodes (p 0.01),
were using bronchodilators on presentation (p 0.0001) and
were less vaccinated for pneumococcus (p 0.004).
Viral detection
Adequate sample was obtained from 566 out of 611 children
(289/312 hospitalized and 277/299 non-hospitalized). One or
more respiratory viruses were detected in 397 of them
(70.1%). Among the positive samples, a single virus was iden-
tified in 228 (57.4%), two viruses in 111 (28%), and three or
more viruses in 58 (14.6%). Detection rates observed among
different age groups were for children 1–12 months 73.6%
(120/163), for 1–5 years 72.3% (191/265), and for 5–14 years
62.3% (86/138), (p 0.061).
The most prevalent viruses during the study period were
RSV in 225 (56.6%) children, PIV in 118 (29.7%) and RV in
73 (18.4%), followed by INFL in 56 (14.1%), ADV in 31
(7.8%), HBoV in 25 (6.3%), HMPV in 15 (3.7%), EV in 12
(3%), and HCoV Type 229 in 2 (0.5%) (Fig. 1).
Viral co-infections were detected in 169 children (42.5%).
The frequency of co-infections were for infants <12 months
33.7% (55/163) and for children >12 months 28.3% (114/
403) (p 0.119). The most frequent viral co-infections were
RSVA-RSVB in 46 children (27.2%), RSV–INFL in 20 (11.8%),
RSV–RV in 18 (10.6%), PIV–RV in 13 (7.7%), PIV–INFL–RSV
in 9 (5.3%), RSV–PIV in 8 (4.7%), RSV–HBoV 5 in (3%), PIV–
INFL in 5 (3%), PIV–RSV–ADV in 5 (3%), RSV–HMPV in 4
(2.3%), RSV–ADV in 3 (1.7%), PIV–ADV in 3 (1.7%), and
PIV–INFL–ADV in 3 (1.7%) (Fig. 2).
There was no difference in the distribution of viruses
between non-hospitalized and hospitalized children, with the
exception of RSV infection, which was detected more fre-
quently in the latter (p 0.011).
Risk factors for hospitalization
Logistic regression analysis showed that the presence of viral
co-infection increased the risk for hospitalization (OR, 1.52;
95% CI, 1.01–2.29; p 0.04). When this analysis was per-
formed only in children who had tested positive for at least
TABLE 1. Distribution of 611 chil-
dren with respiratory tract infec-
tion by demographic and clinical
characteristics and by hospitaliza-
tion status.
Parameter
Hospitalized
(n = 312) n (%)
Non hospitalized
(n = 299) n (%)
p-value derived
from Wilcoxon* or
Chi-square test
Age (months) (mean ± SD) 34.0 ± 36.62 49.8 ± 42.84 0.0001*
Male 180 (57.7) 164 (54.9) 0.48
Family member with ARTI 154 (49.4) 127 (42.5) 0.09
Chronic health problem 36 (11.5) 11 (3.7) 0.0003
Wheezing episodes per year (mean ± SD) 1.5 ± 2.38 1 ± 1.74 0.01*
Fever on presentation 224 (71.8) 187 (62.5) 0.01
Bronchodilator use on presentation 78 (25.0) 17 (5.7) 0.0001
Antibiotic use on presentation 72 (23.1) 63 (21.1) 0.55
No pneumococcal vaccination 111 (35.6) 62 (20.8) 0.0001
No influenza vaccination 279 (89.4) 274 (91.6) 0.35
Days of symptoms on presentation (mean ± SD) 3.5 ± 2.3 3.1 ± 1.9 0.19*
Detection of virus 203/289 (70.2) 194/277 (70.0) 0.99
Viral co-infection 97/289 (47.7) 72/277 (37.1) 0.05
ARTI, acute respiratory tract infection; Chronic health problem, chronic heart, liver, or kidney disease, cystic fibrosis
or diabetes.
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one virus (n = 397) the increased risk for hospitalization
remained (OR, 1.67; 95% CI, 1.061–2.65; p 0.026). Other
risk factors associated with hospitalization were age
<12 months (OR, 4.51; 95% CI, 2.60–7.81; p 0.0001), chronic
health problem (OR, 3.48; 95% CI, 1.61–7.52; p 0.002), his-
tory of wheezing episodes (two more episodes, OR, 1.33;
95% CI, 1.08–1.64; p 0.01), fever on presentation (OR, 2.7;
95% CI, 1.8–4.07; p 0.0001) and bronchodilator use on pre-
sentation (OR, 4.50; 95% CI, 2.45–8.24; p 0.0001) (Table 2).
In contrast, a negative association of pneumococcal vaccina-
tion with risk for hospitalization (OR, 0.52; 95% CI, 0.33–
0.81; p 0.004) was found. Among hospitalized children there
was no statistically significant association of viral co-infections
with use of bronchodilators and fever on presentation or
length of hospitalization.
Discussion
Broadening viral diagnosis in respiratory tract infections may
help clinicians to decrease unnecessary prescriptions of anti-
biotics, implement early antiviral treatments when available,
and prevent virus transmission.
In the present study we used a DNA/RNA microarray
assay that allows detection and identification simultaneously
of 17 types of common and newly discovered human viruses.
This method is versatile and greatly expands the spectrum of
detectable viruses in a single assay, while simultaneously
allowing discrimination among viral subtypes [13].
To the best of our knowledge this is the largest series of
children studied prospectively with the aim of detecting sin-
gle or multiple respiratory viral infections by microarray
technology. Few studies have evaluated the use of micro-
arrays for the detection of multiple respiratory viruses in
children [11,12,14]. The detection rate in these studies,
depending on the clinical syndrome and the assay used, was
between 58 and 85%, which is similar to our study (70.1%).
One of the drawbacks of virus detection by genetic ampli-
fication are false negatives, which are mainly the result of
poor quality of the extracted DNA/RNA caused by an insuf-
ficient quantity of the initial sample, degradation of the virus
genetic material because of inadequate storage of the sample
or its loss during extraction. The presence of inhibitors of
the enzyme mixture (reverse transcriptase and DNA poly-
merase) in samples in which virus detection is going to be
performed (sputum, respiratory secretions etc.) is another
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FIG. 1. Number of positive samples for
17 different viruses or subtypes as single
infections or co-infections detected by
microarrays in 397 children with respi-
ratory tract infections.
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FIG. 2. Viral co-infections that were
detected by microarrays in 397 children
with respiratory tract infections.
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possible explanation. Nevertheless, the assay used in our
study eliminated such false negatives with the addition of an
internal control that was extracted along with any possible
viruses present in the sample and was subsequently amplified
in the reaction tubes, confirming the correct efficiency of
both the extraction and the PCR amplification [15].
In our study a significant proportion of viral co-infections
were detected among children with positive samples (42.5%)
and were associated with increased possibility for hospitaliza-
tion. The prevalence of co-infections in other studies ranged
between 15% and 44% in children seen in the hospital or
emergency department with diverse types of respiratory
tract infections and detection methods [16–24] .
There are conflicting results whether multiple viral infec-
tions are associated with a more severe clinical presentation
compared with a single infection [25]. Semple et al. [21]
reported a ten-fold increase in the relative risk of admission
to a paediatric intensive-care unit for mechanical ventilation
caused by severe bronchiolitis in patients with dual infection
with HMPV and RSV. Paranhos-Baccala et al. [1] showed that
the presence of more than one pathogen, and moreover, the
association of RSV with rhinoviruses or HMPV, might influ-
ence the natural course of bronchiolitis. Other researchers
found that children with HMPV/RSV co-infection were more
likely to develop pneumonia, but they did not manifest
increased disease severity as defined by the duration of hos-
pitalization and need for oxygen supplementation [26]. In
contrast, other investigators failed to demonstrate more
serious disease with dual infections [27–29].
The detection of multiple viruses raises the question if all
viruses that are detected are responsible for the clinical
symptoms or if they are innocent bystanders. These multiple
viruses can be successive infections and molecular tests
could detect a persistent genome in the absence of viral
activity. The DNA microarray assay employed is only a quali-
tative technique not able to identify the predominant viral
agent that could be considered as the cause of the acute
respiratory syndrome. Quantitative PCR methods are proba-
bly a better tool to discriminate between the active virus
and prolonged presence of previous viruses [6,17].
Interestingly, pneumococcal vaccination was associated
with a decreased probability for hospitalization. Pneumococ-
cal interaction with viral pathogens is well established and
can increase the clinical severity of respiratory infections
[30,31].
The present study has limitations because it lasted 1 year
and some viruses have different circulation in the community
in consecutive years. Moreover, there was no quantification
of the viral load or detection of bacterial co-infection. The
specific microarray assay that was used has limited published
clinical validation, especially in the paediatric population. A sig-
nificant number of RSVA–RSVB co-infections were detected
that need further exploration with specific RT-PCR assays to
confirm the specificity of the assay for these viral subtypes.
Additionally, the assay may underestimate the presence of
some viruses like coronaviruses because it can detect only
Coronavirus subtype 229E. In a significant proportion of
children that present with symptoms of respiratory infection,
no viral or bacterial pathogen can be detected by conventional
or molecular methods. This implies that either molecular
methods need further improvement for their sensitivity or
there are still other viruses to be discovered.
The issue of the association of viral co-infection with the
severity of clinical presentation remains controversial. There
is a compelling need to perform multi-centre studies with
common protocols, which will last several years and will
measure the viral load for different viruses in co-infections.
Comparison of viral detection in a control group with
asymptomatic children may help to understand which viruses
can be innocent rhinopharyngeal colonizers.
In conclusion, in our study viral co-infections in children
with respiratory tract infections increased the risk for hospi-
talization. Simultaneous detection of respiratory pathogens
with microarrays may elucidate the interplay between
viruses, bacteria and the host and may determine which viral
pathogens affect the clinical severity of respiratory infections.
TABLE 2. Multiple logistic analysis derived odds ratios (OR)
and 95% confidence intervals (95% CI) for hospitalization by
demographic and clinical characteristics.
Variables
Category or
increment OR 95% CI p-value
Age <12 months 4.51 2.60 7.81 0.0001
12–59 1.45 0.92 2.30 0.11
60+ Baseline
Sex Female 1.00 0.70 1.44 0.99
Male Baseline
Family member
with ARTI
Yes 1.03 0.72 1.49 0.86
No Baseline
Chronic health
problem
Yes 3.48 1.61 7.52 0.002
No Baseline
No. of wheezing
episodes per year
Two more 1.33 1.08 1.64 0.01
Fever on
presentation
Yes 2.70 1.80 4.07 0.0001
No Baseline
Bronchodilator use
on presentation
Yes 4.50 2.45 8.24 0.0001
No Baseline
Antibiotic use on
presentation
Yes 0.93 0.60 1.45 0.75
No Baseline
Influenza vaccination Yes 1.83 0.99 3.36 0.06
No Baseline
Pneumococcal
vaccination
Yes 0.52 0.33 0.81 0.004
No Baseline
Additionally introduced variable, available for 566 children
Viral co-infection Yes 1.52 1.01 2.29 0.04
No Baseline
ARTI, acute respiratory tract infection; Chronic health problem, chronic heart,
liver, or kidney disease, cystic fibrosis or diabetes; Pneumococcal vaccination, at
least one dose.
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